New hope for breast cancer patients when first treatment fails

NCT ID NCT05305924

Recruiting now Disease control Sponsor: The Methodist Hospital Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, fulvestrant and abemaciclib, for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a first-line treatment called a CDK4/6 inhibitor. The goal is to see if taking a break from the first drug and switching to this new combo can help control the cancer again. About 28 participants will be enrolled, and the main focus is on how long the treatment works before the cancer progresses again.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

estrogen-receptor positive breast cancer Her2-receptor negative breast cancer hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ER POSITIVE BREAST CANCER HER2-NEGATIVE BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Houston Methodist Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.